Last reviewed · How we verify

Standard dose of rituximab

Second Affiliated Hospital, School of Medicine, Zhejiang University · FDA-approved active Small molecule

Standard dose of rituximab is a Monoclonal antibody (anti-CD20) Small molecule drug developed by Second Affiliated Hospital, School of Medicine, Zhejiang University. It is currently FDA-approved for Non-Hodgkin's lymphoma (B-cell), Chronic lymphocytic leukemia (CLL), Rheumatoid arthritis.

Rituximab is a chimeric monoclonal antibody that binds to CD20 on B cells, leading to their depletion through antibody-dependent cellular cytotoxicity and direct apoptosis.

Rituximab is a chimeric monoclonal antibody that binds to CD20 on B cells, leading to their depletion through antibody-dependent cellular cytotoxicity and direct apoptosis. Used for Non-Hodgkin's lymphoma (B-cell), Chronic lymphocytic leukemia (CLL), Rheumatoid arthritis.

At a glance

Generic nameStandard dose of rituximab
SponsorSecond Affiliated Hospital, School of Medicine, Zhejiang University
Drug classMonoclonal antibody (anti-CD20)
TargetCD20
ModalitySmall molecule
Therapeutic areaOncology, Immunology
PhaseFDA-approved

Mechanism of action

Rituximab targets the CD20 antigen expressed on the surface of B lymphocytes. Upon binding, it triggers multiple mechanisms of B cell destruction including antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and direct induction of apoptosis. This results in rapid depletion of B cells, reducing autoimmune responses and malignant B cell populations.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Standard dose of rituximab

What is Standard dose of rituximab?

Standard dose of rituximab is a Monoclonal antibody (anti-CD20) drug developed by Second Affiliated Hospital, School of Medicine, Zhejiang University, indicated for Non-Hodgkin's lymphoma (B-cell), Chronic lymphocytic leukemia (CLL), Rheumatoid arthritis.

How does Standard dose of rituximab work?

Rituximab is a chimeric monoclonal antibody that binds to CD20 on B cells, leading to their depletion through antibody-dependent cellular cytotoxicity and direct apoptosis.

What is Standard dose of rituximab used for?

Standard dose of rituximab is indicated for Non-Hodgkin's lymphoma (B-cell), Chronic lymphocytic leukemia (CLL), Rheumatoid arthritis, Granulomatosis with polyangiitis (GPA), Microscopic polyangiitis (MPA).

Who makes Standard dose of rituximab?

Standard dose of rituximab is developed and marketed by Second Affiliated Hospital, School of Medicine, Zhejiang University (see full Second Affiliated Hospital, School of Medicine, Zhejiang University pipeline at /company/second-affiliated-hospital-school-of-medicine-zhejiang-university).

What drug class is Standard dose of rituximab in?

Standard dose of rituximab belongs to the Monoclonal antibody (anti-CD20) class. See all Monoclonal antibody (anti-CD20) drugs at /class/monoclonal-antibody-anti-cd20.

What development phase is Standard dose of rituximab in?

Standard dose of rituximab is FDA-approved (marketed).

What are the side effects of Standard dose of rituximab?

Common side effects of Standard dose of rituximab include Infusion reactions, Infections, Cytopenias (anemia, thrombocytopenia, neutropenia), Fatigue, Fever, Nausea.

What does Standard dose of rituximab target?

Standard dose of rituximab targets CD20 and is a Monoclonal antibody (anti-CD20).

Related